Evidence map›Paper›PMID 42288551›Full record

ArticleScientific reports2026

Genome near-haploidization in CDC73-wildtype parathyroid tumors.

Maaia Margo Jentus, Filomena Cetani, Marieke Snel, Femke M van Haalen, Dina Ruano, Natasha M Appelman-Dijkstra, Abbey Schepers, Stijn Crobach, Claudio Marcocci, Liborio Torregrossa and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maaia Margo JentusDepartment of Pathology, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333, ZA, The Netherlands. m.jentus@lumc.nl.ORCID http://orcid.org/0000-0001-5724-7643
Filomena CetaniDepartment of Clinical and Experimental Medicine, Endocrine Unit, University of Pisa, Pisa, Italy.
Marieke SnelDepartment of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.
Femke M van HaalenDepartment of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.
Dina RuanoDepartment of Pathology, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333, ZA, The Netherlands.
Natasha M Appelman-DijkstraDepartment of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.
Abbey SchepersDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Stijn CrobachDepartment of Pathology, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333, ZA, The Netherlands.
Claudio MarcocciDepartment of Clinical and Experimental Medicine, Endocrine Unit, University of Pisa, Pisa, Italy.
Liborio TorregrossaDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Hans MorreauDepartment of Pathology, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333, ZA, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parathyroid carcinoma (PC) is most often linked to germline or somatic CDC73 mutations. Previously, we identified three CDC73-wildtype PCs with massive chromosomal losses and genome near-haploidization, with or without endoreduplication/genome doubling - features also seen in rare tumor types such as oncocytic thyroid carcinoma. To assess whether similar alterations occur in other parathyroid neoplasms, we analyzed fourteen parathyroid adenomas (PA; thirteen oncocytic), three atypical parathyroid tumors (APTs; one oncocytic), and one additional PC, the latter four all CDC73-wildtype. Histopathological diagnoses followed the 2022 WHO classification. Genome-wide SNP array analysis was performed to detect copy number variations (CNVs), imbalances and loss of heterozygosity (LOH). APTs and PC underwent somatic mutation analysis, to confirm CDC73-wildtype status. Oncocytic PAs exhibited largely stable genomes, with few or no chromosomal alterations. Patients with chromosomally altered PA had significantly higher preoperative serum calcium levels. In contrast, two of three APTs, and the included PC displayed extensive chromosomal losses and genome near-haploidization. These findings expand the recognized spectrum of chromosomal alterations in CDC73-wildtype parathyroid tumors.

Indexed as

Parathyroid NeoplasmsTumor Suppressor ProteinsDNA Copy Number VariationsFemaleHumansLoss of HeterozygosityMaleMutationPolymorphism, Single NucleotideCDC73 protein, humanTumor Suppressor ProteinsEndocrine pathologyMolecular analysisParathyroidParathyroid carcinomaParathyroid neoplasiaRare cancerWhole chromosome loss

Identifiers

PMID42288551
PMCPMC13522456

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.